Humana Inc. (NYSE:HUM) has emerged as a top-ranked value play within the healthcare sector following its stock price’s sharp 26.64% year-to-date decline.Valuation Vs. MomentumAfter a significant sector-wide sell-off triggered by the Donald Trump administration's proposed flat Medicare Advantage (MA) rates, Humana's value Score on the Benzinga Edge’s Stock Ranking dashboard surged from 77.65 to 86.97.This percentile-ranked metric indicates that the company is now priced attractively relative to its fundament ...

We recently published 10 Big Names With Painful Declines. Humana Inc. (NYSE:HUM) was one of the worst performers on Tuesday. Humana fell by 21.13 percent on Tuesday to finish at $207.93 apiece, tracking the decline in insurance companies following a flat funding in Medicare Advantage for 2027. According to an advanced notice released on Monday, the Centers for Medicare & Medicaid Services (CMS) announced only a 0.09 percent increase in Medicare Advantage payments for next year, far lower than the 4 to 6 ...

Core Viewpoint - Humana's stock experienced a significant decline of 21% following the CMS's announcement of a minimal rate increase for 2027, highlighting the company's vulnerability as a "pure play" on Medicare Advantage, which constitutes approximately 85% of its operations [2] Financial Performance - Humana's Q3 2025 revenue was reported at $32.65 billion, reflecting an 11% year-over-year increase, while adjusted EPS for the same period was $3.24, down 22% year-over-year [2] - The medical benefit ratio for Q3 2025 stood at 91.1%, indicating limited profitability potential, as ratios above 90% are generally unfavorable [3] - The company anticipates a full-year 2025 adjusted EPS of around $17.00, with a projected benefit ratio between 90.1% and 90.5% [3] Membership Trends - Humana is facing a decline in Medicare Advantage membership, with an expected loss of approximately 425,000 members in 2025 due to withdrawal from unprofitable markets [3] Star Ratings Impact - Humana's Star Ratings, which influence bonus payments from CMS, have significantly dropped for the bonus year 2027, leading to reduced reimbursements and a competitive disadvantage compared to peers like UnitedHealth [5] Valuation Insights - Following the recent stock decline, Humana is trading at around $209 per share, approximately 13 times the estimated 2026 EPS, which appears slightly undervalued compared to historical multiples of 16-18 times [6] - The company is focusing on operational efficiencies and aims to achieve over $100 million in savings through AI and outsourcing [6] Future Projections - Analysts project a loss of $4.00 per share for Q4 2025, contrasting with a loss of $2.16 in Q4 2024, reflecting the challenges in addressing the Star Ratings issue [7] - The company is implementing a "reset" strategy for 2025-2026, but its effectiveness remains unproven amid regulatory challenges [8] Investment Outlook - The investment view suggests that Humana presents a high-risk profile until Q4 results and final 2027 rates are disclosed, with a 35% analyst upside projection considered optimistic given existing structural hurdles [9]

U.S. stock markets are poised for a pivotal Wednesday, January 28th, 2026, as investors keenly await the Federal Reserve's latest interest rate decision and a flurry of earnings reports from influential technology giants. Premarket trading indicates a mixed but generally upward trend for futures, with the tech-heavy Nasdaq leading the charge, signaling continued optimism in the artificial intelligence (AI) sector.Premarket Activity and Futures MovementsAs the trading day begins to unfold, U.S. stock index f ...

Group 1: Hong Kong Stock Market Performance - Most property stocks in Hong Kong rose, with China Jinmao (00817) up 7.95%, Greentown China (03900) up 5.79%, and China Overseas Macro Yang Group (00081) up 4.62%. Vanke Enterprises (02202) also saw a gain of 2.49% following significant progress in debt resolution, with the extension proposals for two medium-term notes totaling 5.7 billion yuan approved [1][1]. - Pop Mart (09992) increased by over 4.8%, reflecting confidence in its development as it recently repurchased shares for the first time since early 2024, which is expected to attract more investors [1][1]. - Nanshan Aluminum International (02610) rose over 4.7% after announcing plans to invest approximately 4.37 billion USD (about 30.56 billion yuan) in a new aluminum project in Indonesia [1][1]. Group 2: Notable Company Announcements - Alibaba Health (00241) rose over 3.3% after launching a new feature for its AI medical application "Hydrogen Ion" [2][2]. - GCL Global (GCL.US) increased by 9.91% ahead of its earnings call scheduled for January 30, 2026 [5][5]. - Ericsson (ERIC.US) continued its upward trend with a 4.03% increase after reporting a strong Q4 2025 financial performance, with adjusted EBITA rising 24% year-on-year [5][5]. Group 3: Market Trends and Price Adjustments - The gold market saw a significant rise, with spot gold prices surpassing 5200 USD, leading to a 7.38% increase in the shares of Wan Guo Gold Group (03939) [2][2]. - The semiconductor sector showed strong performance, with stocks like Naxin Micro (02676) up 10.62% and a price adjustment announcement from Zhongwei Semiconductor indicating a price increase of 15% to 50% due to supply-demand pressures [3][4]. - The storage sector also experienced a pre-market surge, with Micron Technology (MU.US) up 5.44% as price increases spread across the storage market [7][7].

CNBC's Jim Cramer said Tuesday that President Donald Trump is a force to be reckoned with in the stock market — but whether he's helping or hurting companies depends on where they sit. "You have to factor in the government as both a positive and a negative, no matter what you do," Cramer said on "Mad Money," after outlining the impact of the president's agenda on five stocks that had notable moves in Tuesday's session. First, Cramer pointed to a group that got crushed on Tuesday: the nation's largest health ...

Back to Market on Close. I'm Marley Kaden alongside Sam Bodis in New York. Healthc care stocks the worst performers in the S&P 500.Today for more on the sector and why we're seeing so much downward pressure. Joining us now, David Tongue, the senior analyst in healthcare at Argust Research. David, thank you so much for being with us.You know, we've got this announcement on the new proposed rate for Medicare Advantage. Following that, we saw about $90 billion in market cap get wiped from the healthcare insura ...

美国医疗保险和医疗补助服务中心(CMS)在公告中表示，预计2027年联邦医保优势计划(Medicare Advantage)的支付费率仅将上调0.09%，远低于分析师此前预期的高达6%的增幅。支付费率对联合健 康、西维斯健康和哈门那等大型保险商至关重要。支付费率提高能帮助保险公司覆盖医疗成本、提升老 年客户福利并增厚利润，而小幅上调则会直接压缩企业利润率。 周二，医疗保险股盘前集体大跌，哈门那(HUM.US)股价重挫逾16%，联合健康(UNH.US)大跌15%，西 维斯健康(CVS.US)跌近10%。消息面上，美国政府提议明年将联邦医疗保险(Medicare)私人计划的支付 费率维持在当前水平，这一消息令投资者大失所望。 另外，联合健康公布的第四季度盈利略微超出预期，但2026年收入指引疲软。根据LSEG汇编的数据， 联合健康第四季度经调整后每股收益为2.11美元，高于分析师平均预期的2.10美元。Q4营收为1132亿美 元，尽管同比增长约12%，但仍比华尔街预期低5.2亿美元。该公司还预测，2026年收入将出现下滑， 这将是三十多年来收入首次年度萎缩。 ...

智通财经APP获悉，周二，医疗保险股盘前集体大跌，哈门那(HUM.US)股价重挫逾16%，联合健康 (UNH.US)大跌15%，西维斯健康(CVS.US)跌近10%。消息面上，美国政府提议明年将联邦医疗保险 (Medicare)私人计划的支付费率维持在当前水平，这一消息令投资者大失所望。 另外，联合健康公布的第四季度盈利略微超出预期，但2026年收入指引疲软。根据LSEG汇编的数据， 联合健康第四季度经调整后每股收益为 2.11 美元，高于分析师平均预期的 2.10 美元。Q4营收为 1132 亿美元，尽管同比增长约 12%，但仍比华尔街预期低5.2亿美元。该公司还预测，2026 年收入将出现下 滑，这将是三十多年来收入首次年度萎缩。 美国医疗保险和医疗补助服务中心(CMS)在公告中表示，预计2027年联邦医保优势计划(Medicare Advantage)的支付费率仅将上调0.09%，远低于分析师此前预期的高达6%的增幅。支付费率对联合健 康、西维斯健康和哈门那等大型保险商至关重要。支付费率提高能帮助保险公司覆盖医疗成本、提升老 年客户福利并增厚利润，而小幅上调则会直接压缩企业利润率。 ...

Humana跌17%，Elevance Health跌8%，Centene跌超7%。 (本文来自第一财经) Humana跌17%，Elevance Health跌8%，Centene跌超7%。 (本文来自第一财经) ...